Article Cited by others

ORIGINAL ARTICLE

Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study

Zhao Jin-Ge, Liu Jian-Dong, Shen Peng-Fei, Tang Xin, Sun Guang-Xi, Zhang Xing-Ming, Chen Jun-Ru, Shu Kun-Peng, Shi Ming, Zeng Hao

Year : 2018| Volume: 20| Issue : 6 | Page no: 545-550

   This article has been cited by
 
1 Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer
Kotaro Suzuki,Tomoaki Terakawa,Katsumi Shigemura,Junya Furukawa,Kenichi Harada,Nobuyuki Hinata,Yuzo Nakano,Masato Fujisawa
Molecular and Clinical Oncology. 2019;
[Pubmed]  [Google Scholar] [DOI]
2 Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study
Taro Iguchi,Satoshi Tamada,Minoru Kato,Sayaka Yasuda,Taiyo Otoshi,Kosuke Hamada,Takeshi Yamasaki,Tatsuya Nakatani
International Journal of Clinical Oncology. 2019;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article